Allos Therapeutics (ALTH) To Present Data for FOLOTYN Phase 2b in Patients with Stage IIIB/IV NSCLC
Tweet Send to a Friend
Allos Therapeutics, Inc. (Nasdaq: ALTH) announced that they will be presenting data from a Phase 2b investigational trial of FOLOTYN ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
